65937-01-1

Basic information

• Product Name: 2-bromo-3-4-dimethylpropiophenone
• Synonyms: 2-bromo-3-4-dimethylpropiophenone
• CAS NO: 65937-01-1
• Molecular Formula: C₁₁H₁₃BrO
• Molecular Weight: 241.127
• Mol File: 65937-01-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-bromo-3-4-dimethylpropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-3-4-dimethylpropiophenone(65937-01-1)
• EPA Substance Registry System: 2-bromo-3-4-dimethylpropiophenone(65937-01-1)

Safety Data

• Hazardous Substances Data: 65937-01-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-3-4-dimethylpropiophenone is used as a key intermediate in the production of psychoactive substances and various medicinal and chemical compounds. It plays an important role in the development and production of these substances due to its unique chemical properties.
Used in Research and Development:
2-bromo-3-4-dimethylpropiophenone is used as a precursor in the synthesis of research chemicals, enabling scientists to explore new compounds and their potential applications in various fields.
Note: Due to the potential for misuse and abuse, 2-bromo-3-4-dimethylpropiophenone is regulated in many countries. It should be stored and handled under strict laboratory conditions to minimize potential hazards.

Upstream product

• 17283-12-4 1-(3,4-dimethylphenyl) propan-1-one 
• 95-47-6 o-xylene 
• 563-76-8 α-bromopropionyl bromide 

Downstream Products

• 806601-27-4 (3,4-Dimethyl-phenyl)-(1-dimethylamino-ethyl)-keton 

Relevant articles and documents

Novel benzene-based carbamates for ache/bche inhibition: Synthesis and ligand/structure-oriented sar study

A series of new benzene-based derivatives was designed, synthesized and comprehensively characterized. All of the tested compounds were evaluated for their in vitro ability to potentially inhibit the acetyl-and butyrylcholinesterase enzymes. The selectivity index of individual molecules to cholinesterases was also determined. Generally, the inhibitory potency was stronger against butyryl-compared to acetylcholinesterase; however, some of the compounds showed a promising inhibition of both enzymes. In fact, two compounds (23, benzyl ethyl(1-oxo-1-phenylpropan-2-yl)carbamate and 28, benzyl (1-(3-chlorophenyl)-1-oxopropan-2-yl) (methyl)carbamate) had a very high selectivity index, while the second one (28) reached the lowest inhibitory concentration IC50 value, which corresponds quite well with galanthamine. Moreover, comparative receptor-independent and receptor-dependent structure–activity studies were conducted to explain the observed variations in inhibiting the potential of the investigated carbamate series. The principal objective of the ligand-based study was to comparatively analyze the molecular surface to gain insight into the electronic and/or steric factors that govern the ability to inhibit enzyme activities. The spatial distribution of potentially important steric and electrostatic factors was determined using the probability-guided pharmacophore mapping procedure, which is based on the iterative variable elimination method. Additionally, planar and spatial maps of the host–target interactions were created for all of the active compounds and compared with the drug molecules using the docking methodology.

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.